Top Page
Oncimmune Holdings
(LSE:ONC)
Oncimmune Holdings (ONC) vs. iShares MSCI United Kingdom ETF (EWC)
Oncimmune Holdings Business Overview & Revenue Model
Oncimmune Holdings Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.21M | 2.74M | 1.15M | 3.86M | 3.72M | 509.00K | Gross Profit |
| 484.00K | 1.23M | 792.00K | 1.46M | 2.86M | -28.00K | EBIT |
| -1.78M | -3.23M | -4.24M | -8.59M | -5.14M | -9.27M | EBITDA |
| -1.34M | -3.00M | -4.43M | -7.16M | -4.48M | -8.97M | Net Income Common Stockholders |
| 7.06M | -3.63M | 4.10M | -9.51M | -4.63M | -8.46M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 7.51M | 846.00K | 3.21M | 2.53M | 8.63M | 4.24M | Total Assets |
| 12.80M | 4.90M | 8.44M | 17.26M | 24.28M | 10.31M | Total Debt |
| 8.59M | 5.12M | 5.30M | 10.69M | 9.47M | 8.28M | Net Debt |
| 1.08M | 4.28M | 2.09M | 8.16M | 837.00K | 4.04M | Total Liabilities |
| 10.52M | 7.30M | 7.78M | 19.98M | 19.05M | 10.51M | Stockholders Equity |
| 2.29M | -2.40M | 657.00K | -2.73M | 5.23M | -194.00K |
| Cash Flow | Free Cash Flow | ||||
| -6.14M | -3.39M | -6.82M | -6.71M | -5.60M | -9.14M | Operating Cash Flow |
| -6.13M | -3.38M | -6.79M | -6.21M | -4.53M | -8.90M | Investing Cash Flow |
| 11.05M | 1.16M | 11.58M | -504.00K | -856.00K | 347.00K | Financing Cash Flow |
| -5.04M | -71.00K | -3.02M | 987.00K | 9.78M | 7.46M |
Oncimmune Holdings Technical Analysis
Oncimmune Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% | |
49 Neutral | £5.05M | ― | -46.71% | ― | -100.00% | 26.23% | |
47 Neutral | £18.82M | ― | -87.30% | ― | ― | 71.17% | |
38 Underperform | £1.36M | ― | -116.39% | ― | -21.33% | -2.50% | |
32 Underperform | $1.27M | 1.35 | ― | 137.76% | -193.86% |
Oncimmune Holdings Corporate Events
Oncimmune Holdings plc announced the appointment of Simon Bonney and James Varney as joint administrators by IPF Invest Co 2 S.A.R.L. This development led to the resignation of Cavendish Capital Markets Limited as the company’s Nominated Adviser and Joint Broker, with Zeus Capital Limited also resigning as Joint Broker. The company has no plans to appoint a replacement Nominated Adviser, which could result in the cancellation of its shares’ admission to trading on AIM if not addressed within a month. Stakeholders and potential asset acquirers are advised to contact the joint administrators.
Oncimmune Holdings PLC has announced a change in the voting rights held by Balderton Capital III, LP, which now holds 5.87% of the voting rights in the company, down from a previous 6.09%. This adjustment in holdings may impact the company’s shareholder dynamics and influence its strategic decisions moving forward.
Oncimmune Holdings plc has announced its intention to appoint administrators and suspend trading of its shares on AIM due to its inability to secure a buyer for its subsidiary, Oncimmune Germany GmbH, or raise necessary capital for short-term funding. The decision to enter administration is aimed at preserving the business’s value for creditors, with Alvarez & Marsal Europe LLP set to be appointed as administrators.
Oncimmune Holdings Plc held a General Meeting where all proposed resolutions were passed as ordinary resolutions. The resolutions included the approval of the report and accounts, the remuneration report, the appointment of an auditor, and the remuneration of the auditor. This successful meeting reflects strong shareholder support and could positively impact Oncimmune’s operations and strategic positioning in the precision medicine industry.
Oncimmune Holdings Plc announced the successful passing of both resolutions at its Annual General Meeting held in London. The resolutions included the authority to allot shares and the disapplication of statutory pre-emption rights, both of which received overwhelming support from shareholders. This outcome reflects strong shareholder confidence and supports Oncimmune’s strategic initiatives in precision medicine, potentially enhancing its market positioning and operational capabilities.
Oncimmune Holdings plc has announced a strategic update following a recent decline in its share price, highlighting efforts to seek strategic partnerships and additional financing. The company has appointed Alvarez & Marsal to pursue potential partners and investors, while engaging in discussions for fundraising to extend its cash runway beyond April 2025. Despite current financial challenges, Oncimmune remains optimistic about its long-term prospects, with ongoing projects and significant potential contracts that could materially impact its financial performance.
Oncimmune Holdings PLC, a UK-based company, announced a change in voting rights as Spreadex LTD acquired and disposed of certain financial instruments and voting rights. This update reflects a shift in ownership percentages, with Spreadex now holding a total of 2.6774% of Oncimmune’s voting rights, down from a previous position of 3.8444%. The notification underscores the dynamic changes within shareholder structures that may impact the company’s governance and stakeholder engagement.
Oncimmune Holdings has announced the posting of a notice of a General Meeting to shareholders, which will occur on March 10, 2025, to approve the company’s Annual Report and Accounts for the financial year ending August 31, 2024. This meeting is significant as it will address the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing future collaborations and market positioning.